{"nctId":"NCT03389555","briefTitle":"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial","startDateStruct":{"date":"2018-02-09","type":"ACTUAL"},"conditions":["Sepsis","Septic Shock","Metabolic Disturbance"],"count":205,"armGroups":[{"label":"Vitamin C, Vitamin B1, Corticosteroids","type":"EXPERIMENTAL","interventionNames":["Drug: vitamin C, vitamin B1, hydrocortisone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal saline"]}],"interventions":[{"name":"vitamin C, vitamin B1, hydrocortisone","otherNames":["Ascorbic Acid","Thiamine"]},{"name":"Normal saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adult patient (age ≥ 18 years)\n2. Suspected (cultures drawn and antibiotic given) or confirmed (via culture results) infection\n3. Receiving vasopressor (norepinephrine, phenylephrine, epinephrine, dopamine, angiotensin II or vasopressin)\n\nExclusion Criteria:\n\n1. Member of a protected population (pregnant, prisoner)\n2. Known kidney stones within the past 1 year (except for asymptomatic, incidentally noted stones on imaging)\n3. End stage renal disease (ESRD) requiring dialysis\n4. Known Glucose-6-Phosphate Dehydrogenase deficiency\n5. Known Hemachromatosis\n6. Comfort Measures Only status\n7. Anticipated death within 24-hours despite maximal therapy (as determined by the enrolling physician)\n8. Receiving supplemental thiamine in a dose greater than that contained in a multivitamin\n9. Clinical indication for steroids (e.g. chronic use) as determined by the clinical team providing this drug\n10. Clinical indication for thiamine as determined by the clinical team providing this drug\n11. Clinical indication for ascorbic acid as determined by the clinical team providing this drug\n12. Known allergy to vitamin C, hydrocortisone, or thiamine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours","description":"Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours. The SOFA score ranges from a minimum of 0 to a maximum of 24, with higher scores meaning worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"3.5"},{"groupId":"OG001","value":"9.2","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"4.1"},{"groupId":"OG001","value":"5.1","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Renal Failure","description":"Development of renal failure as defined by a Kidney Disease Improving Global Outcomes \\[KDIGO\\] stage 3 or higher. There are 3 stages in the KDIGO scale with stage 3 being the worst (corresponds to renal failure).\n\nStage 1- serum creatinine 1.5 to 1.9 times baseline OR an increase in serum creatinine ≥ 0.3 mg/dL OR urine output \\< 0.5ml/kg/hour for 6-12 hours. Stage 2- serum creatinine 2.0-2.9 times baseline OR urine output \\<0.5mg/kg/hour for ≥ 12 hours Stage 3- serum creatinine 3.0 times baseline (or serum creatinine of more than or equal to 4.0 mg/dl with an acute increase of at least 0.5 mg/dl) (OR) Urine output less than 0.3 ml/kg/hour for 24 hours or anuria for 12 hours or new renal replacement therapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"30-day Mortality","description":"Mortality rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ventilator Free Days","description":"Days not receiving invasive mechanical ventilation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Shock Free Days","description":"Days not receiving vasopressor","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"ICU Free Days","description":"Number of days that the patient was not in the ICU. Timeframe listed below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hospital Mortality","description":"Hospital mortality rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Intensive Care Unit (ICU) Mortality","description":"ICU mortality rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Delirium","description":"Describes if patient has delirium as defined by the Confusion Assessment Method (CAM)-ICU. The CAM-ICU method requires that the patient have 3 features to qualify for delirium:\n\n1. Acute Onset of Changes or Fluctuations in the Course of Mental Status (AND )\n2. Inattention (AND)\n3. Disorganized thinking (OR) Altered Level of Consciousness","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hospital Disposition: Survivors Discharged Home","description":"Home hospital disposition in patients who survive to discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":101},"commonTop":[]}}}